Yidu Tech (2158) H1 2026 earnings summary

Executive summary

• H1 FY2026 revenue rose 8.7% YoY to RMB358.1m; loss narrowed 72.0% to RMB15.8m as operating loss fell and operating cash outflow declined.�

• Policy tailwinds supported order growth; combined cash, deposits and restricted balances were RMB2,099.3m at 30 September 2025.�

Financial highlights

• Revenue was RMB358.1m, up 8.7% YoY; gross profit rose 14.2% to RMB134.0m.�

• Operating loss narrowed 71.0% to RMB15.7m; period loss narrowed 72.0% to RMB15.8m.�

• Net fair-value gains of RMB16.8m and provision reversals of RMB10.2m contributed to other gains of RMB24.5m, versus RMB2.7m a year earlier.�

• Net cash used in operating activities was RMB51.3m, down 56.0% YoY; basic and diluted loss per share was RMB0.01 versus RMB0.04.�

Outlook and guidance

• Priorities: scale intelligent-agent deployment, deepen disease research and applications, combine human expertise with AI, and enrich the ecosystem through partnerships, investments and acquisitions.�

• BDPS plans broader hospital and regional coverage and deeper specialty disease models; LSS aims to extend intelligence from clinical development through post-launch commercialization.�

• HMPS plans to expand user coverage, improve health-related quality of life and platform engagement, and develop an AI-driven health-management model.�